These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33081161)

  • 21. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
    J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.
    Hobbs RF; Howell RW; Song H; Baechler S; Sgouros G
    Radiat Res; 2014 Jan; 181(1):90-8. PubMed ID: 24502376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
    Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
    J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter Therapy.
    Hobbs RF; Howell RW; Song H; Baechler S; Sgouros G
    Radiat Res; 2013 Dec; ():. PubMed ID: 24377718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.
    Baechler S; Hobbs RF; Prideaux AR; Wahl RL; Sgouros G
    Med Phys; 2008 Mar; 35(3):1123-34. PubMed ID: 18404947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
    Eberlein U; Cremonesi M; Lassmann M
    J Nucl Med; 2017 Sep; 58(Suppl 2):97S-103S. PubMed ID: 28864620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
    Chittenden SJ; Hindorf C; Parker CC; Lewington VJ; Pratt BE; Johnson B; Flux GD
    J Nucl Med; 2015 Sep; 56(9):1304-9. PubMed ID: 26182965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls.
    Ivashchenko OV; O'Doherty J; Hardiansyah D; Cremonesi M; Tran-Gia J; Hippeläinen E; Stokke C; Grassi E; Sandström M; Glatting G
    Phys Med; 2024 Jan; 117():103192. PubMed ID: 38052710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward theragnostics.
    Pene F; Courtine E; Cariou A; Mira JP
    Crit Care Med; 2009 Jan; 37(1 Suppl):S50-8. PubMed ID: 19104225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outpatient therapeutic nuclear oncology.
    Turner JH
    Ann Nucl Med; 2012 May; 26(4):289-97. PubMed ID: 22222779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
    Garin E; Tselikas L; Guiu B; Chalaye J; Edeline J; de Baere T; Assenat E; Tacher V; Robert C; Terroir-Cassou-Mounat M; Mariano-Goulart D; Amaddeo G; Palard X; Hollebecque A; Kafrouni M; Regnault H; Boudjema K; Grimaldi S; Fourcade M; Kobeiter H; Vibert E; Le Sourd S; Piron L; Sommacale D; Laffont S; Campillo-Gimenez B; Rolland Y;
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):17-29. PubMed ID: 33166497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(16):1-167. PubMed ID: 23074467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy.
    Ferrari ME; Cremonesi M; Di Dia A; Botta F; De Cicco C; Sarnelli A; Pedicini P; Calabrese M; Orecchia R; Pedroli G; Paganelli G
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1702-11. PubMed ID: 22890802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3D calculation of absorbed dose for 131I-targeted radiotherapy: a Monte Carlo study.
    Saeedzadeh E; Sarkar S; Abbaspour Tehrani-Fard A; Ay MR; Khosravi HR; Loudos G
    Radiat Prot Dosimetry; 2012 Jul; 150(3):298-305. PubMed ID: 22069233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment planning for radio-immunotherapy.
    Erdi AK; Erdi YE; Yorke ED; Wessels BW
    Phys Med Biol; 1996 Oct; 41(10):2009-26. PubMed ID: 8912377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
    Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
    Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.